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Abstract
Background: To examine whether a loading dose of ticagrelor on top of clopidogrel reduced post-
percutaneous coronary intervention (PCI) myonecrosis.
Methods: Seventy seven coronary artery disease patients received a loading dose of 300 mg clopidogrel 
pre-PCI and were divided into three groups: group TT (n = 36): a loading dose of 180 mg ticagrelor 
pre-PCI, followed by ticagrelor 90 mg twice daily  commencing one day post-PCI; group CT (n = 26): 
a maintenance dose of ticagrelor 90 mg twice daily; group CC (n = 15): clopidogrel 75 mg daily post-
PCI. High sensitivity cardiac troponin T (hs-cTnT) and creatine kinase-MB (CK-MB) were measured 
pre-PCI and 0 h, 2 h or 24 h post-PCI. Platelet aggregation was measured in a separate cohort of  
54 coronary artery disease patients (35 diabetic and 19 non-diabetic patients). 
Results: There were no significant differences in hs-cTnT and CK-MB concentration among the three 
groups. In group TT, diabetic patients had significant higher Dhs-cTnT2h–0h than non-diabetic patients. 
In the second cohort, although baseline platelet aggregation was higher in diabetic than non-diabetic 
patients, platelet aggregation was comparable between diabetic and non-diabetic patients at 0 and 2 h 
post-PCI. 
Conclusions: This study indicates that a loading dose of ticagrelor does not significantly reduce post-
PCI myonecrosis. Diabetes is associated with more post-PCI myonecrosis. A loading dose of ticagrelor 
effectively reduces platelet aggregation in diabetic patients. (Cardiol J 2017; 24, 1: 15–24)
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Introduction
Dual antiplatelet therapy with aspirin and 
a P2Y12 inhibitor is the standard of care for acute 
coronary syndrome (ACS) [1, 2]. Clopidogrel, 
a thienopyridine, is a prodrug that undergoes 
hepatic conversion, therefore leading to a delayed 
onset of action and substantial variability between 
individuals in levels of platelet inhibition. Up to one 
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with inadequate platelet inhibition [3]. Ticagrelor, 
a reversible and direct-acting oral P2Y12-receptor 
antagonist, provides greater and more consistent 
platelet inhibition than clopidogrel, with more rapid 
onset and offset of action [4–6]. In the PLATelet 
inhibition and patient Outcomes (PLATO) trial, 
reversible long-term P2Y12 inhibition with tica-
grelor was better than that with clopidogrel for 
the prevention of cardiovascular and total death, 
myocardial infarction (MI), and stent thrombosis, 
without an increase in the rates of major bleeding in 
a broad population of patients with ACS, who began 
treatment upon hospital admission [7, 8]. Although 
a loading dose of ticagrelor was used in PLATO 
trial [9], a recent study demonstrated that a loading 
dose of ticagrelor was not associated with a further 
platelet inhibition after switching from clopidogrel 
to ticagrelor for patients with ACS receiving on-
going clopidogrel treatment [10]. However, the 
above study only included clopidogrel responders 
[10]. It is known that a large number of patients 
with coronary artery disease (CAD) have diabetes 
and patients with diabetes had a higher number of 
clopidogrel non-responders, and increased platelet 
reactivity compared with nondiabetic subjects on 
combined aspirin and clopidogrel treatment [11]. 
Since ticagrelor has a higher potency of platelet 
inhibition [12], and stronger anti-inflammatory 
effect and vascular endothelial protection [13] 
compared to clopidogrel, it is herein hypothesized 
that an additional dose of ticagrelor might improve 
myonecrosis post-percutaneous coronary interven-
tion (PCI). Therefore, in this observational study, 
the aim was to assess whether the administration 
of a loading dose of ticagrelor on top of clopidogrel 
reduces myocardial necrosis (measured by high 
sensitivity cardiac troponin T (hs-TnT) and cre-
atine kinase-MB (CK-MB), after PCI in patients 
with stable CAD in relation to diabetic status. 
Methods
Study patients  
Patients with stable CAD who successfully 
underwent PCI at Xinhua Hospital, Shanghai, 
China were recruited between 1 January and 
31 July 2014. Patients with class III/IV heart failure, 
abnormal liver or renal function, various inflam-
matory diseases or incorporative infection were 
excluded from the study. A total of 83 patients were 
included in the present study and all patients were 
given 300 mg clopidogrel loading dose before coro-
nary angiography. Patients were divided into three 
groups: 1) group TT received additional 180 mg 
ticagrelor loading dose before PCI, and followed by 
a maintenance dose of 90 mg ticagrelor twice daily 
from the next day before and after PCI; 2) group 
CT received a maintenance dose of 90 mg ticagre-
lor twice daily before and after PCI; 3) group CC 
patients continued clopidogrel 75 mg daily therapy. 
Six patients were excluded due to acute myocardial 
ischemia caused by injury of side branch during PCI 
procedure. A total of 77 patients were finally in-
cluded in this prospective study (group TT: n = 36, 
group CT: n = 26, and group CC: n = 15). All 
three groups were given 100 mg aspirin and 10 mg 
rosuvastatin daily. Baseline patient characteristics 
included age, sex and cardiovascular risk factors 
such as smoking, family history, hypertension 
and diabetes. The use of angiotensin converting 
enzyme inhibitors or angiotensin receptor block-
ers, calcium channel blockers, beta-blockers and/ 
/or antidiabetic therapy (including insulin or oral 
medication) was decided on an individual basis by 
the attending physician. 
In order to investigate the antiplatelet ef-
ficiency of a loading dose of ticagrelor in diabetic 
patients, another cohort of 54 patients with CAD 
were recruited and divided into diabetic group 
(n = 35) and non-diabetic group (n = 19) according 
to the global guideline for type 2 diabetes. Patients 
in both groups received 180 mg ticagrelor loading 
dose before PCI, and was followed by 90 mg tica-
grelor twice daily before and after PCI. All patients 
were given 100 mg aspirin and 10 mg rosuvastatin 
daily. Baseline patient characteristics and medica-
tion details were recorded as above.
The present study complied with the Declara-
tion of Helsinki and was registered in the Chinese 
Clinical Trial Registry (no. ChiCTR-TRC-14004377; 
http://www.chictr.org) and approved by the Ethics 
Committee of Experimental Research, Jiaotong 
University. All patients provided written informed 
consent.
Percutaneous coronary intervention
Percutaneous coronary intervention was per-
formed via the radial artery according to standard 
clinical practice. The recorded coronary angiogra-
phy films were analyzed with SYNTAX Score to 
evaluate the complexity of the coronary lesions 
by two experienced cardiologists blinded to the 
patient’s clinical and laboratory data. Each coro-
nary lesion producing a ≥ 50% luminal obstruction 
in vessels ≥ 1.5 mm was scored and collected to 
generate the SYNTAX score. The calculation was 
performed with the website-based SYNTAX calcu-
lator version 2.28 (www.syntaxscore.com). More-
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over, the following PCI-related parameters were 
also collected including the number of diseased 
vessels and the number of stents implanted. More 
than 50% stenosis of the vessel was considered as 
a diseased vessel and culprit lesions with ≥ 75% 
stenosis were dilated and subsequently stented 
with drug-eluting stents. A vascular segment 
was considered to have been treated successfully 
when residual luminal narrowing in the dilated 
segment immediately after PCI was < 5%. The 
PCI procedure was considered successful when 
the target lesion was successfully treated without 
causing major complications (electrocardiographic 
or enzymatic evidence of new MI and or the need 
for bypass surgery during hospitalization or in-
hospital death). 
Biochemical analysis
Blood was taken the morning before coronary 
angiography and also before the loading dose of 
P2Y12 antagonists for baseline measurements. 
Serum samples were obtained by centrifuging the 
blood at 1600 g for 15 min at room temperature 
within 30 min of venipuncture and aliquots were 
stored immediately at –80°C for future analysis. 
Total cholesterol, low density lipoprotein choles-
terol, high density lipoprotein cholesterol and tri-
glycerides were determined by enzymatic methods 
on the day of blood collection in the laboratories 
of the Xinhua Hospital. Fasting plasma glucose 
was measured by the hexokinase method. Serum 
hypersensitive C-reactive protein was detected by 
the particle-enhanced turbidimetric immunoassay. 
Serum aspartate aminotransferase, alanine ami-
notransferase, blood urea nitrogen and creatinine 
were detected using routine biochemical methods. 
All assays were performed in a blinded manner.
hs-cTnT and CK-MB measurements 
Ten mL of blood samples for hs-cTnT and 
CK-MB testing were drawn into heparin tubes 
in each patient before PCI and 0 h, 2 h after PCI. 
Blood samples were centrifuged at 3,000 g for 
10 min at room temperature and then plasma samples 
were stored at –80°C for future analysis. Plasma 
levels of hs-cTnT were analyzed using the new 
hs-cTnT quantitative electro chemiluminescence 
immunoassay (Roche Diagnostics, Mannheim, Ger-
many). The lower detection limit is 0.01 μg/L with 
a recommended diagnostic threshold of 0.03 μg/L 
(hs-cTnT levels were detectable in all patients). 
Plasma levels of CK-MB were measured by enzyme 
linked immunosorbent assay (ELISA).
Platelet aggregation test
Blood samples were collected before PCI (also 
before admission of ticagrelor) and 0 h, 2 h after PCI. 
Platelet aggregation were determined by light trans-
mission aggregometry (LBY-NJ4, PRECIL, Beijing, 
China) according to the guide of manufacturer in the 
central laboratory of the Xinhua Hospital.
Statistical analysis 
Baseline demographics of patients between 
groups were compared with the c2 test or Fisher’s 
exact test for dichotomous variables and the one-way 
ANOVA test for continuous variables, as appropri-
ate. Comparisons of concentrations of hs-cTnT or 
bleeding events between the three groups were 
achieved by one-way ANOVA test and Kruskal-
-Wallis H test, respectively. Spearman correlation 
analysis was performed to assess the correlations 
between log-transformed hs-cTnT at 2 h after PCI 
and baseline characteristics. Variables with p < 0.15 
from spearman correlation analysis were included in 
multivariable linear regression analysis to evaluate 
independent predictors of hs-cTnT at 2 h after PCI. 
Continuous variables were expressed as mean ± 
standard deviation, if not stated otherwise. A two-
-sided p-value of < 0.05 was considered significant. All 
statistical analyses were performed with IBM SPSS 
statistics for Windows 19.0 (SPSS, Inc., Chicago, IL).
Results
Population characteristics
Baseline variables were comparable among 
group TT, CT and CC (Table 1) except that there 
were fewer men and fewer hypertensive patients 
in group TT. For the second cohort of 54 CAD 
patients recruited for investigation on the effects 
of ticagrelor on platelet aggregation in diabetes, 
baseline variables were comparable among diabetic 
(n = 35) and non-diabetic patients (n = 19) (Table 2).
Myocardial necrosis
No significant differences were observed 
among the three groups (TT, CT and CC) in serum 
hs-cTnT concentrations before PCI and at 0 h, 
or 2 h after PCI (Fig. 1A). hs-cTnT was slightly 
increased at 2 h after PCI in both group CT and 
group CC, however, they were slightly decreased in 
group TT when compared to 0 h after PCI, but this 
difference was not significant (Fig. 1C). Similarly, 
no significant differences were found in CK-MB 
levels before PCI, and at 0 h or 24 h among the 
three groups (Fig. 1B). 
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The influence of diabetic status 
The effects of a loading dose of ticagrelor on 
myocardial necrosis separately in diabetic and 
non-diabetic patients were noted (Fig. 2). Pa-
tients were stratified according to the presence 
of type 2 diabetes. Both hs-cTnT (Fig. 2A, B) and 
CK-MB (Fig. 2C, D) did not differ significantly 
among the three groups in either diabetic or non-
diabetic patients. A comparison was made, hs-cTnT 
(Fig. 3A–C) and CK-MB (Fig. 3D–F) between 
diabetic and non-diabetic separately in groups 
TT, CT and CC. There were no significant differ-
ences in hs-cTnT and CK-MB at the different time 
points (above) between diabetic and non-diabetic 
patients in individual groups. We further compared 
△hs-cTnT2h–0h between diabetic and non-diabetic 
patients in groups TT, CT and CC (Fig. 3G–I). In 
group TT, diabetic patients had significantly higher 
△hs-cTnT2h–0h than non-diabetic patients (Fig. 3G). 
The difference in △hs-cTnT2h–0h between diabetic 
and non-diabetic patients in group CT or CC was 
not significant (Fig. 3H, I).
Platelet aggregation 
Attention was then turned as to whether 
higher △hs-cTnT2h–0h levels after PCI in diabetic 
Table 1. Baseline characteristics — TT, CT and CC groups.
Group TT (n = 36) Group CT (n = 26) Group CC (n = 15) P 
Demographics:
Age [years] 66.1 ± 10.1 65.8 ± 10.4 66.9 ± 10.5 0.920
Male 20 (56%) 23 (88%) 12 (80%) 0.014
Medical history:
Family history of CAD 3 (8%) 1 (4%) 2 (13%) 0.548
Hypertension 17 (47%) 18 (69%) 13 (87%) 0.021
Diabetes 11 (31%) 9 (35%) 5 (33%) 0.943
Prior myocardial infarction 7 (19%) 3 (12%) 3 (20%) 0.673
Smoking 13 (36%) 11 (42%) 6 (40%) 0.883
Baseline medications:
Statin 35 (97%) 26 (100%) 15 (100%) 1.000
ACEI or ARB 16 (44%) 14 (54%) 11 (73%) 0.174
Beta-blocker 34 (97%) 25 (96%) 15 (100%) 0.985
Calcium-channel blocker 0 (0%) 4 (15%) 2 (13%) 0.058
Hypoglycemic agent 10 (28%) 9 (35%) 4 (27%) 0.810
Baseline laboratory data:
HSCRP [mg/L] 2.57 ± 2.65 2.54 ± 3.54 2.50 ± 2.62 0.475
ALT [U/L] 22 ± 14 19 ± 7 36 ± 48 0.233
AST [U/L] 21 ± 8 18 ± 8 26 ± 18 0.052
Cholesterol [mmol/L] 4.04 ± 1.21 4.03 ±0.82 3.77 ± 0.69 0.646
Triglyceride [mmol/L] 1.83 ± 1.47 1.69 ± 1.17 1.33 ± 0.51 0.916
LDL [mmol/L] 2.35 ± 0.90 2.53 ± 0.69 2.48 ± 0.56 0.124
HDL [mmol/L] 1.32 ± 0.31 1.31 ± 0.26 1.49 ± 0.36 0.312
Glucose [mmol/L] 5.58 ± 1.35 6.17 ± 2.02 6.03 ±1.88 0.748
BUN [μmol/L] 5.34 ± 1.14 5.73 ± 1.24 5.57 ± 1.28 0.540
Creatinine [mmol/L] 65.9 ± 17.7 74.1± 16.7 69.7 ± 15.2 0.210
Coronary angiography details:
SYNTAX Score 14.9 ± 1.7 11.3 ± 1.5 13.5 ± 2.4 0.338
Number of lesions 1.8 ± 0.9 1.5 ± 0.7 1.7 ± 0.8 0.441
Number of stents 1.5 ± 0.6 1.3 ± 0.5 1.2 ± 0.4 0.110
CAD — coronary artery disease; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; HSCRP — hypersen-
sitive C reactive protein; ALT — alanine transaminase; AST — aspartate transaminase; LDL — low-density lipoprotein; HDL — high-density 
lipoprotein; BUN — blood urea nitrogen
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Table 2. Baseline characteristics — diabetic and non-diabetic patients.
DM (n = 35) Non-DM (n = 19) P 
Demographics:
Age [years] 70 ± 9 68 ± 15 0.793
Male 16 (46%) 12 (63%) 0.225
Medical history:
Family history of CAD 22 (63%) 12 (63%) 0.983
Hypertension 32 (91%) 14 (74%) 0.082
Diabetes 35 (100%) 0 (0%) 0.000
Post PCI 12 (34%) 4 (21%) 0.314
Smoking 9 (26%) 7 (37%) 0.397
Baseline medications:
ACE inhibitors/ARBs 23 (66%) 12 (63%) 0.852
Beta-blocker 33 (94%) 16 (84%) 0.227
Calcium-channel blocker 7 (20%) 2 (11%) 0.377
Hypoglycemic agent 21 (60%) 0 (0%) 0.000
Baseline laboratory data:
HSCRP [mg/L] 2.33 ± 2.71 6.38 ± 23.20 0.321
ALT [U/L] 19 ± 8 23 ± 21 0.942
AST [U/L] 19 ± 5 25 ± 17 0.085
Cholesterol [mmol/L] 3.83 ± 1.01 4.26 ± 1.01 0.085
Triglyceride [mmol/L] 1.54 ± 0.86 1.68 ± 1.22 0.971
LDL [mmol/L] 2.18 ± 0.68 2.42 ± 0.60 0.133
HDL [mmol/L] 1.27 ± 0.29 1.37 ± 0.24 0.077
Glucose [mmol/L] 7.20 ± 2.47 5.20 ± 0.73 0.000
BUN [μmol/L] 6.15 ± 2.34 5.13 ± 1.36 0.147
Creatinine [mmol/L] 73.4 ± 16.2 74.0 ± 17.5 0.779
DM — diabetes mellitus; CAD — coronary artery disease; PCI — percutaneous coronary intervention; ACE — angiotensin-converting enzyme; 
ARBs — angiotensin II receptor blockers; HSCRP — hypersensitive C reactive protein; ALT — alanine transaminase; AST — aspartate 
transaminase; LDL — low-density lipoprotein; HDL — high-density lipoprotein. BUN — blood urea nitrogen
Figure 1. The effects of loading dose of ticagrelor on myocardial necrosis. All patients were given clopidogrel 300 mg 
loading dose before coronary angiography. Group TT (n = 36) received a loading dose of 180 mg ticagrelor pre 
percutaneous coronary intervention (PCI) and a maintenance dose of ticagrelor 90 mg twice per day commencing 
the day after PCI. Group CT (n = 26) received a maintenance dose of ticagrelor 90 mg twice pear day post PCI while 
group CC (n = 15) continued clopidogrel 75 mg daily. Concentrations of high sensitivity cardiac troponin T (hs-cTnT) 
(A) and creatine kinase-MB (CK-MB) (B) were measured before PCI and at 0 h and 2 h after PCI in these three groups; 
C. Delta change of hs-cTnT at 2 h relative to 0 h after PCI in groups TT, CT and CC; hs-cTnT = hs-cTnT2h – hs-cTnT0h. 
Data are shown as mean ± SEM. 
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patients were associated with higher platelet ag-
gregation in a separate cohort of CAD patients 
receiving a loading dose of 180 mg ticagrelor be-
fore PCI. Baseline platelet aggregation rate was 
significantly higher in diabetic patients compared 
to non-diabetic patients (Fig. 4A). Platelet aggrega-
tion was significantly reduced at 0 h and 2 h after 
PCI in both diabetic and non-diabetic patients due 
to the effect of a loading dose of ticagrelor (Fig. 4A). 
The reduction of platelet aggregation rate was 
greater in diabetic patients than non-diabetic pa-
tients at 0 h after PCI (Fig. 4B).
Associations between hs-cTnT levels  
and baseline characteristics
As shown in Figure 1, at 2 h after PCI hs-cTnT 
levels increased slightly in all groups compared to 
baseline levels. Since hs-cTnT was influenced by 
a lot of other factors [14], we intended to know 
whether baseline characteristics affected serum 
hs-cTnT concentrations at 2 h after PCI (Table 3). 
Only baseline hs-cTnT remained significantly cor-
related with hs-cTnT at 2 h after PCI in multivari-
able analysis. None of the baseline characteristics 
were independent factors affecting hs-cTnT at 2 h 
after PCI in stable CAD patients.
Bleeding events
A comparison was made of the total number 
of bleeding events among the three groups in 
diabetic and non-diabetic patients as well as the 
total number of bleeding events between diabetic 
and non-diabetic patients in groups TT, CT and 
CC (Table 4) over a 1 month period subsequent to 
PCI. No significant differences in bleeding events 
(whether major or minor bleeding) were found 
among groups independent of loading dose of 
ticagrelor or diabetic status. 
Discussion
In stable CAD patients already receiving 
a loading dose of 300 mg clopidogrel, an additional 
loading dose of 180 mg ticagrelor did not sig- 
nificantly lower hs-cTnT or CK-MB concentration 
after PCI. After we stratified patients according 
Figure 2. Concentrations of high sensitivity cardiac troponin T (hs-cTnT) and creatine kinase-MB (CK-MB) in diabetic 
and non-diabetic patients. All patients were given clopidogrel 300 mg loading dose before coronary angiography. 
Group TT (n = 36) received a loading dose of 180 mg ticagrelor pre percutaneous coronary intervention (PCI) and 
a maintenance dose of ticagrelor 90 mg twice per day commencing the day after PCI. Group CT (n = 26) received 
a maintenance dose of ticagrelor 90 mg twice per day post PCI while group CC (n = 15) continued clopidogrel 75 mg 
daily. hs-cTnT (A) or CK-MB (C) in non-diabetic patients in these three groups. hs-cTnT (B) or CK-MB (D) in diabetic 
patients in these three groups. Data are shown as mean ± SEM; DM — diabetes mellitus. 
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Figure 3. Concentrations of high sensitivity cardiac troponin T (hs-cTnT), creatine kinase-MB (CK-MB) and delta 
change of hs-cTnT in diabetic and non-diabetic patients. All patients were given clopidogrel 300 mg loading dose 
before coronary angiography. Group TT (n = 36) received a loading dose of 180 mg ticagrelor pre percutaneous 
coronary intervention (PCI) and a maintenance dose of ticagrelor 90 mg twice per day from the next day after PCI. 
Group CT (n = 26) received a maintenance dose of ticagrelor 90 mg twice per day post PCI while group CC (n = 15) 
continued clopidogrel 75 mg daily. Comparison in hs-cTnT between diabetic and non-diabetic patients in group TT (A), 
group CT (B) and group CC (C). Comparison in CK-MB between diabetic and non-diabetic patients in group TT (D), 
group CT (E) and group CC (F). Comparison in delta change of hs-cTnT between diabetic and non-diabetic patients in 
group TT (G), group CT (H), and group CC (I). Data are shown as mean ± SEM; DM — diabetes mellitus; *p < 0.05. 
to the presence of type 2 diabetes, we found that 
in the patient group who received a loading dose 
of ticagrelor, diabetic patients had higher △hs- 
-cTnT2h–0h than non-diabetic patients. A loading 
dose of ticagrelor did not increase bleeding events 
in both diabetic and non-diabetic patients. Platelet 
aggregation was compared in a separate cohort of 
CAD patients who received a loading dose of 180 mg 
ticagrelor before PCI. Baseline platelet aggrega-
tion was higher in diabetic patients compared to 
non-diabetic patients, but platelet aggregation at 
0 h and 2 h after PCI was similar for both diabetic 
and non-diabetic patients, suggesting that a loading 
dose of 180 mg ticagrelor before PCI effectively 
reduces platelet aggregation in diabetic patients 
to the comparable level in non-diabetic patients. 
hs-cTnT assays have significantly improved 
the sensitivity for early diagnosis of acute MI 
as early as 2 h after patients are presented with 
chest pain [15–17]. Platelet aggregation is also 
significantly reduced 2 h after the first adminis-
tration of ticagrelor [10]. So hs-cTnT was chosen 
at 2 h after PCI as a parameter to reflect whether 
a loading dose of ticagrelor could decrease post-PCI 
myocardial necrosis in stable CAD patients already 
receiving clopidogrel therapy. Myocardial necrosis, 
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which can range from a minor elevation of cardiac 
enzymes to a large infarct, is the most common 
complication following PCI. Microembolization 
of plague debris during PCI procedure has been 
proposed as the most likely cause of myocardial 
necrosis [18], and myocardial necrosis could also 
be associated with ischemia and reperfusion injury 
after stent implantation and sudden blood supply 
of ischemic myocardial tissues [19]. Cardiac tro-
ponins are a more sensitive marker than CK-MB 
in detecting minor degrees of myocardial necrosis 
following PCI [20, 21]. Previous studies have 
suggested that elevation of troponins after PCI is 
predictive of future cardiac events [22, 23]. In the 
present study, we did not observe that a loading 
dose of ticagrelor significantly decreased hs-cTnT 
or CK-MB after PCI. It has been reported that the 
increase in hs-cTnT concentration could be due to 
Figure 4. Residual platelet aggregation level in diabetic patients and non-diabetic patients with admission of 180 mg 
ticagrelor loading dose. Patients received 180 mg loading ticagrelor pre percutaneous coronary intervention (PCI), 
and followed by ticagrelor 90 mg twice per day commencing the day after PCI; A. Platelet aggregation in both dia-
betic (DM, n = 35) and non-diabetic (non-DM, n = 19) patients pre PCI, and 0 h and 2 h after PCI; B. The reduction of 
platelet aggregation at 0 h and 2 h after PCI relative to pre PCI value in both DM and non-DM groups. Data are shown 
as mean ± SEM; DM — diabetes mellitus; *p < 0.05.
Table 4. Bleeding events in 1 month after percutaneous coronary intervention.
Non-diabetes mellitus patients Diabetes mellitus patients













Bleeding events 3 (12%) 2 (12%) 0 (0%) 0.524 1 (9%) 0 (0%) 0 (0%) 0.529
Table 3. Association between high sensitivity cardiac troponin T (hs-cTnT) levels and population  
characteristics.
Characteristic Univariable Multivariable
Spearman correlation P b P
Sex –0.183 0.111
Prior MI 0.187 0.103
hs-cTnT 0.283 0.013 12.279 0.014
Creatinine 0.244 0.033 0.005 0.058
MI — myocardial infarction
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other non-ischemic factors such as heart failure, 
diabetes mellitus and ventricular hypertrophy 
[14, 24]. Correlation analysis was done between 
hs-cTnT2h after PCI and baseline characteristics of 
patients, and it was found that hs-cTnT2h after PCI 
was strongly associated only with baseline hs-cTnT 
level, but not with other factors, suggesting that 
hs-cTnT levels at 2 h after PCI in our patients is 
not significantly affected by other factors.
Patients were then stratified according to the 
presence of type 2 diabetes mellitus. There were 
no significant differences in patients’ characteris-
tics at baseline between diabetic and non-diabetic 
patients in each group, but diabetic patients had 
a tendency of more previous MI and higher fasting 
blood glucose levels (data not shown). We found 
that in the group receiving additional loading dose 
of ticagrelor, diabetic patients had higher △hs-
cTnT2h–0h than non-diabetic patients. It was then 
examined as to whether higher △hs-cTnT2h–0h 
after PCI in diabetic patients were associated with 
higher platelet aggregation in a separate cohort 
of CAD patients receiving 180 mg loading dose of 
ticagrelor before PCI. Baseline platelet aggregation 
rate was higher in diabetic when compared to non-
diabetic patients, as seen in the another study [11], 
but a loading dose of ticagrelor lowered platelet 
aggregation level in diabetic patients to a compa-
rable level in non-diabetic patients at 0 h and 2 h 
after PCI. So, △hs-cTnT2h–0h was higher after PCI 
in diabetic when compared to non-diabetic patients 
but a comparable platelet aggregation rate between 
diabetic and non-diabetic patients indicate that 
other factors such as inflammation, blood glucose, 
microenvironment or vascular abnormality may 
have contributed to myocardial necrosis following 
PCI [25].
Limitations of the study
The present study has several limitations. 
First, it was a single center design study with 
a relatively small sample size. Second, this study 
used hs-cTnT concentration instead of periproce-
dural MI as an endpoint. So, larger-scale studies 
with periprocedural MI as an endpoint are needed 
for further research.
Conclusions
In conclusion, our study indicates that admin-
istration of a loading dose of ticagrelor does not 
significantly impact post-PCI myonecrosis in CAD 
patients. Diabetes is associated with higher △hs-
cTnT2h–0h after PCI in patients receiving a loading 
dose of ticagrelor, which evidently is not due to 
a higher platelet aggregation in diabetic patients. 
A loading dose of ticagrelor effectively reduces 
platelet aggregation in diabetic patients to a com-
parable level in non-diabetic patients.
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